Baldewig Malte, Goldbaum Olaf, Richter-Landsberg Christiane, Weyland Andreas, Bantel Carsten
Department of Anesthesiology, Klinikum Oldenburg, Oldenburg, Germany.
Molecular Neurobiology, Department of Neuroscience, University of Oldenburg, Oldenburg, Germany.
J Pain Res. 2018 Jun 20;11:1181-1190. doi: 10.2147/JPR.S162322. eCollection 2018.
Gabapentinoids are currently the mainstay of pharmacological treatments for patients with neuropathic pain. Little is known about the effects of this therapy on the integrity of neuronal networks, especially in patients with an already-damaged nervous system. Since gabapentinoids can worsen cognitive functions and recent studies have shown alterations in the brains of patients with neuropathic pain, it may be possible that these drugs have neurotoxic effects.
Rat clonal PC12 pheochromocytoma (autonomic) and primary sensory dorsal-root ganglion (DRG) neurons from newborn Wistar rats were employed for this study. To mimic neuronal damage, cells were exposed to cytotoxins using either hydrogen peroxide (HO) or vincristine.
No direct cytotoxic effects were observed after incubating PC12 cells for 24 hours with increasing concentrations of gabapentin or pregabalin using MTT cytotoxicity assays. Even a 7-day incubation did not cause cellular damage. Furthermore, in preinjured PC12 and DRG neurons, neither gabapentin nor pregabalin prevented or enhanced the cytotoxic effects of HO or vincristine after incubation for 24 hours and 7 days, respectively. Cell morphology and integrity of the cytoskeleton assessed by employing immunostaining of cytoskeletal proteins (α-tubulin, neurofilament L) remained intact and were not altered by gabapentinoids.
Based on these results, gabapentinoids are unlikely to be neurotoxic in cultured autonomic (PC12) and sensory DRG cells, even when cells are preinjured. These results are of high clinical relevance, as it seems unlikely that the morphological changes recently observed in the brains of neuropathic pain patients are caused or worsened by gabapentinoids.
加巴喷丁类药物目前是治疗神经性疼痛患者的主要药物疗法。对于这种疗法对神经网络完整性的影响,人们知之甚少,尤其是在神经系统已经受损的患者中。由于加巴喷丁类药物会使认知功能恶化,且最近的研究表明神经性疼痛患者的大脑存在变化,这些药物可能具有神经毒性作用。
本研究采用大鼠克隆PC12嗜铬细胞瘤(自主神经)细胞和新生Wistar大鼠的初级感觉背根神经节(DRG)神经元。为模拟神经元损伤,使用过氧化氢(HO)或长春新碱使细胞接触细胞毒素。
使用MTT细胞毒性测定法,将PC12细胞与浓度不断增加的加巴喷丁或普瑞巴林孵育24小时后,未观察到直接的细胞毒性作用。即使孵育7天也未导致细胞损伤。此外,在预先损伤的PC12和DRG神经元中,加巴喷丁和普瑞巴林在分别孵育24小时和7天后,均未预防或增强HO或长春新碱的细胞毒性作用。通过对细胞骨架蛋白(α-微管蛋白、神经丝L)进行免疫染色评估的细胞形态和细胞骨架完整性保持完整,且未被加巴喷丁类药物改变。
基于这些结果,加巴喷丁类药物在培养的自主神经(PC12)和感觉DRG细胞中不太可能具有神经毒性,即使细胞预先受到损伤。这些结果具有高度临床相关性,因为最近在神经性疼痛患者大脑中观察到的形态学变化似乎不太可能由加巴喷丁类药物引起或使其恶化。